Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

Sepsis, Severe Clinical Trial

— ReActiF-ICE  

Official title:

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05442710
• Other study ID #: ReActIF-ICE_ZKSJ0124
• Status: Recruiting
• Phase: Phase 2
• Start date: July 24, 2022
• Est. completion date: May 31, 2025

Study information

• Verified date: February 2024
• Source: Artcline GmbH
• Contact: Jens Altrichter, MD
• Phone: +49 381-440-703
• Email: jens.altrichter[@]artcline.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluation of a novel therapy approach for severe sepsis patients. Subjects randomized into the treatment arm receive treatment with an immune cell perfusion system on top of standard care. This may contribute to the improvement of the impaired organ function of septic shock patients by assisting the impaired immune system (immune competence enhancement = ARTICE)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 142
• Est. completion date: May 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adult subjects

1. = 18 years of age

2. with septic shock, defined as those with septic shock according to" Sepsis-3-Definition" who additionally require norepinephrine at a dose of = 0.15 mcg/kg/min (and/or vasopressin at any dose) for a minimum of 6 hours (within the last 48 hours), to maintain a MAP =65 mmHg

3. Subjects = 80 years of age shall have a Clinical Frailty Scale of <5 to be enrolled.

2. Fulfillment of the definition of septic shock, not longer than 48h before randomization. I.e. the 48h start at the end of the 6h period.

3. Blood lactate >2 mmol/L despite adequate volume resuscitation during the current sepsis episode

4. Source control achieved / in progress in the judgement of the investigator

5. Subjects are required to have central venous access and an arterial line, and these are expected to remain present for at least the initial 48 hours of study.

6. Subjects must have received adequate volume replacement in the judgement of the investigator.

7. Subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or confirmation of the urgency of participation in the clinical trial and the possible benefit to the subject by an independent consultant or the implementation of other established procedures according to the local regulations of the contributing centre to include subjects who are unable to provide informed consent.

Exclusion Criteria:

1. Acute or chronic leukemia,

2. Bilirubin = 2 mg/dL (=33 µmol/L),

3. Ongoing (concomitant) or prior within the last 6 month any chemotherapy or radiotherapy for malignancy,

4. Autoimmune disease with systemic medication of =10 mg prednisolone equivalent,

5. Previous transplantation,

6. Subjects receiving interferon therapy (14 days prior randomisation),

7. Acute pulmonary embolism within the last 72 hours,

8. Ischemic stroke or intracranial bleeding within the last 3 months

9. Suspicion of concomitant acute coronary syndrome based on clinical symptoms and/or ECG within the last 72 hours,

10. Cardiopulmonary resuscitation within last 7 days,

11. Moribund subject (life expectancy <72 hours), in the judgement of the investigator

12. Presence of a do-not-resuscitate or do-not-intubate order,

13. Known HIV infection or chronic viral hepatitis,

14. Isolated Urosepsis,

15. Pregnancy/nursing period,

16. Primary cause of hypotension not due to sepsis (e.g. major trauma including traumatic brain injury, haemorrhage, burns, or congestive heart failure/cardiogenic shock),

17. Previous sepsis with ICU admission within this hospital stay,

18. Known/suspected acute mesenteric ischaemia,

19. Chronic mechanical ventilation for any reason OR severe COPD requiring either continuous daily oxygen use during the preceding 30 days or mechanical ventilation (for acute exacerbation of COPD) during the preceding 30 days,

20. Decision to limit full care taken before obtaining informed consent,

21. Prior enrolment in the trial,

22. Prior use of an investigational medicinal product within the last month OR planned or concurrent participation in a clinical trial for any investigational drug or device,

23. multiple injuries including polytrauma and burn >20% TBSA (2° or 3°),

24. Diagnosed and documented pre-existing dementia,

25. Severe Covid-Pneumonia

Related Conditions & MeSH terms

• Sepsis
• Sepsis, Severe

Intervention

Biological:
• ARTICE
Extracorporal treatment with purified granulocyte concentrate

Locations

Country	Name	City	State
Germany	Charité Berlin, Klinik mit Schwerpunkt Nephrologie und internistische Intensivmedizin	Berlin
Germany	Klinikum Braunschweig, Medizinische Klinik V	Braunschweig
Germany	Universitätsklinikum Freiburg, Interdisziplinäre Medizinische Intensivtherapie (IMIT)	Freiburg	Baden-Württemberg
Germany	Universitätsklinikum Halle (Saale), Universitätsklinik für Anästhesiologie und Operative Intensivmedizin	Halle (Saale)	Sachsen-Anhalt
Germany	UNIVERSITÄTSKLINIKUM Schleswig-Holstein Campus Kiel	Kiel	Schleswig Holstein
Germany	Universitätsklinikum Köln, Klinik für Anästhesiologie und Operative Intensivmedizin	Köln	Nordrhein-Westfalen
Germany	Universitätsklinikum Leipzig, Klinik und PK für Anästhesiologie und Intensivtherapie	Leipzig	Sachsen
Germany	Klinikum Magdeburg, Klinik für Intensiv- und Rettungsmedizin	Magdeburg
Germany	Klinikum Oldenburg, Universitätsklinik für Anästhesiologie/ Intensivmedizin	Oldenburg
Germany	Universitätsmedizin Rostock, Abteilung KAI	Rostock

Sponsors (3)

Lead Sponsor	Collaborator
Artcline GmbH	CRO Kottmann, Zentrum für Klinische Studien Jena

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of the ARTICE therapy, composed of new onset of serious adverse events from re-evaluation on Day 2 through Day 28	The number [n] of new onsets of serious adverse events (SAEs) from re-evaluation-Day 2 through Day 28 will be counted in both arms and the difference between groups will be compared.	From re-evaluation on Day 2 through Day 28
Secondary	All cause mortality through Day 28	The difference in all-cause mortality from re-evaluation on Day 2 through Day 28 will be measured by time to event and Relative risk as well as Kaplan-Meier estimates with 95%-CI will be calculated through day 28	From re-evaluation on Day 2 through Day 28
Secondary	All cause mortality through Day 90	The difference in all-cause mortality from re-evaluation on Day 2 through Day 90 will be measured by time to event and Relative risk as well as Kaplan-Meier estimates with 95%-CI will be calculated through day 90	From re-evaluation on Day 2 through Day 90
Secondary	All-cause in-hospital mortality	The difference in all-cause mortality from re-evaluation on Day 2 through hospital discharge will be measured by time to event and Relative risk as well as Kaplan-Meier estimates with 95%-CI will be calculated through hospital discharge.	From re-evaluation on Day 2 through until hospital discharge
Secondary	Daily changes in total SOFA and SOFA sub-scores	The SOFA (Sequential organ failure assessment score) Score URL"Sequential Organ Failure Assessment (SOFA) Score - MDCalc" is measured by addition of 6 Subscores for each of the 6 Organs between 1 and 4 [n]. The Change from Baseline (COBL) inbetween groups will be compared daily until day 10.; Total score ranges from 0 (best) to 24 (worst); Subscores range from 0 (best) to 4 (worst)	Until Day 10
Secondary	Time course of key inflammatory/ immunological markers in between the two groups.	Time course of key inflammatory/ immunological markers including mHLA-DR and cytokines, measured by their concentration in plasma in pg/mL or in % (HLA-DR) until day 28. Their plasma concentration will be compared by each day inbetween groups.	From re-evaluation on Day 2 until Day 28
Secondary	Time to complete organ failure resolution	The Time to complete organ failure resolution of the 6 organs of the SOFA system (measured as the time from a Baseline value>1 until the score/subscore is 0) through Day 14 and Day 21 will be measured and the time to resolution for all failed organs as a Kaplan Meier Model.	From re-evaluation on Day 2 until Day 28 with special focus on D14 an D21
Secondary	ICU length of stay Measured / Confirmed on day 28 retrospectively. Units: Days	ICU length of stay (through Day 28) will be measured as days [n] in the ICU and compared in between the groups	Until Day 28
Secondary	Number of hospital-free days. Measured / Confirmed on day 28 retrospectively. Units: Days	Hospital length of stay and number of hospital-free days (through Day 28), measured by number of days [n] will be compared between groups Units: Days	Until Day 28
Secondary	Number of ICU-free days Measured / Confirmed on day 28 retrospectively. Units: Days	ICU length of stay and number of ICU-free days (through Day 28), measured by number of days [n] will be compared between groups Units: Days	Until day 28
Secondary	Number of vasopressor- free days	Number of vasopressor- free days [n], until Day 28 Measured / Confirmed on day 28 retrospectively. Units: Days	From re-evaluation on Day 2 until Day 28
Secondary	Number of mechanical-ventilator-free days	Number of mechanical-ventilator-free days [n], until Day 28 Measured / Confirmed on day 28 retrospectively. Units: Days	From re-evaluation on Day 2 until Day 28
Secondary	Number of renal-replacement-free days	Number of renal-replacement-free days [n] until Day 28. Measured / Confirmed on day 28 retrospectively. Units: Days	From re-evaluation on Day 2 until Day 28
Secondary	Number of days without antimicrobial therapy	Number of days [n] without antimicrobial therapy, until Day 28. Measured / Confirmed on day 28 retrospectively. Units: Days	From re-evaluation on Day 2 until Day 28
Secondary	Frequency of secondary infections	Frequency of secondary infections [n], until Day 28. Measured / Confirmed on day 28 retrospectively. Units: total number and days	From re-evaluation on Day 2 until Day 28
Secondary	Antibiotic exposure days until hospital discharge	Antibiotic exposure days [n] until hospital discharge (maximum until Day 28). Measured / Confirmed on day 28 retrospectively. Units: Days	From re-evaluation on Day 2 until Day 28
Secondary	Days [n] alive without antibiotics until hospital discharge	Days alive without antibiotics until hospital discharge (maximum until Day 28). Measured / Confirmed on day 28 retrospectively. Units: Days	From re-evaluation on Day 2 until Day 28
Secondary	Total daily dose of noradrenalin (NA) administered on each day	Total daily dose of noradrenalin (NA) administered on each day measured in mg/kg between Day 2 and Day 10 will be compared in between groups.	From re-evaluation on Day 2 until Day 10
Secondary	Maximum daily dose of noradrenalin administration on treatment days	Maximum daily dose of noradrenalin administration on treatment days between Day 2 and Day 10 (applied for a minimum of 30 min) will be measured as µg/kg/min and compared between the groups for each day until day 10.	From re-evaluation on Day 2 until Day 10
Secondary	Occurrence of virus induced inflammation episodes	Occurrence of virus induced inflammation episodes, especially reactivation of CMV, HSV etc. will be counted as an (S)AE until 28 and the number [n] will be compared between groups.; Measured / Confirmed on day 28 retrospectively.	From re-evaluation on Day 2 until Day 28
Secondary	Quality of life assessment	Quality of life assessed at baseline, Day 28 and Day 90 using EQ-5D-5L Score [n] and compared between the groups.; EQ-5D-5L' is not an abbreviation, it can be described as "EuroQuol - 5 Dimensions - 5 Levels". It considers five dimensions including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression at 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The answers result in a 1-digit number for each dimension. The digits (1= no problem to 5=extreme problems) can be combined into a 5-digit number that describes the patient's health state. 11111 indicates no problems on any of the five dimensions.; The EQ VAS visual analogue scale records the patient's self-rated health. The endpoints are labelled 'The best health you can imagine' (=100) and 'The worst health you can imagine' (=0).	Until day 90
Secondary	Occurrence of cognitive decline	Occurrence of cognitive decline at Day 90 compared with baseline and between groups (measured by IQCODE (Questionnaire on cognitive decline in the elderly); [n]) will be compared between groups.; The IQCODE is scored by averaging the ratings across 26 everyday situations. A person without cognitive decline will have an average score of 3, while scores above 3 indicate that some decline has occurred	Until day 90
Secondary	Time course of key biomarkers of neuroaxonal injury	Time course of key biomarkers of neuroaxonal injury (pg/ml) will be measured in the blood of study patients at predefined time points to assess changes in biomarker levels longitudinally over the course of the disease by comparing them in between groups daily.	Until day 28
Secondary	Inflammatory mRNA profiling analysis	In patients, giving extra informed consent, inflammatory mRNA profiling measured by mRNA occurrence will be analyzed at Day 2 and Day 10 and compared in between Groups.	until day 10